Literature DB >> 19420200

Investigating the natural history of lung function: facts, pitfalls, and opportunities.

Robab Kohansal1, Joan B Soriano2, Alvar Agusti3.   

Abstract

COPD is currently defined as a progressive, preventable, and treatable disease that is characterized by an accelerated decline of lung function. However, contrary to other common chronic conditions like cardiovascular disease or cancer, there are no lifelong population-based studies describing the natural history of lung function and COPD. In this review, we describe the methodology used in population-based studies, both American and European, that have formed the basis of our current understanding of the "natural history" of COPD, including studies with serial pulmonary function testing, which hold potential for further investigations. We highlight the methodological limitations of longitudinal studies and suggest possible solutions. Finally, some characteristics of an "ideal" study on the natural history of lung function decline are recommended, both in health and disease.

Entities:  

Mesh:

Year:  2009        PMID: 19420200     DOI: 10.1378/chest.08-1750

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  14 in total

1.  Rapid lung function decline in smokers is a risk factor for COPD and is attenuated by angiotensin-converting enzyme inhibitor use.

Authors:  Hans Petersen; Akshay Sood; Paula M Meek; Xian Shen; Yan Cheng; Steven A Belinsky; Caroline A Owen; George Washko; Victor Pinto-Plata; Emer Kelly; Bartolome Celli; Yohannes Tesfaigzi
Journal:  Chest       Date:  2014-04       Impact factor: 9.410

2.  Harmonization of Respiratory Data From 9 US Population-Based Cohorts: The NHLBI Pooled Cohorts Study.

Authors:  Elizabeth C Oelsner; Pallavi P Balte; Patricia A Cassano; David Couper; Paul L Enright; Aaron R Folsom; John Hankinson; David R Jacobs; Ravi Kalhan; Robert Kaplan; Richard Kronmal; Leslie Lange; Laura R Loehr; Stephanie J London; Ana Navas Acien; Anne B Newman; George T O'Connor; Joseph E Schwartz; Lewis J Smith; Fawn Yeh; Yiyi Zhang; Andrew E Moran; Stanford Mwasongwe; Wendy B White; Sachin Yende; R Graham Barr
Journal:  Am J Epidemiol       Date:  2018-11-01       Impact factor: 4.897

3.  Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.

Authors: 
Journal:  Lancet Respir Med       Date:  2017-08-16       Impact factor: 30.700

Review 4.  Chronic obstructive pulmonary disease with mild airflow limitation: current knowledge and proposal for future research - a consensus document from six scientific societies.

Authors:  Andrea Rossi; Bojana Butorac-Petanjek; Marco Chilosi; Borja G Cosío; Matjaz Flezar; Nikolaos Koulouris; José Marin; Neven Miculinic; Guido Polese; Miroslav Samaržija; Sabina Skrgat; Theodoros Vassilakopoulos; Andrea Vukić-Dugac; Spyridon Zakynthinos; Marc Miravitlles
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-08-29

5.  Periodontal status and lung function decline in the community: the Hisayama study.

Authors:  Kenji Takeuchi; Koichiro Matsumoto; Michiko Furuta; Satoru Fukuyama; Toru Takeshita; Hiroaki Ogata; Shino Suma; Yukie Shibata; Yoshihiro Shimazaki; Jun Hata; Toshiharu Ninomiya; Yoichi Nakanishi; Hiromasa Inoue; Yoshihisa Yamashita
Journal:  Sci Rep       Date:  2018-09-06       Impact factor: 4.379

6.  COPD as a risk factor of the complications in lower limb arthroplasty: a patient-matched study.

Authors:  Antonio Klasan; Philipp Dworschak; Thomas Jan Heyse; Steffen Ruchholtz; Peter Alter; Claus Franz Vogelmeier; Patrick Schwarz
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-08-21

7.  Health effects of the Federal Bureau of Prisons tobacco ban.

Authors:  Stephen A Martin; Bartolome R Celli; Joseph R DiFranza; Stephen J Krinzman; Jennifer G Clarke; Herbert Beam; Sandra Howard; Melissa Foster; Robert J Goldberg
Journal:  BMC Pulm Med       Date:  2012-10-15       Impact factor: 3.317

8.  Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression.

Authors:  Craig J Galbán; Meilan K Han; Jennifer L Boes; Komal A Chughtai; Charles R Meyer; Timothy D Johnson; Stefanie Galbán; Alnawaz Rehemtulla; Ella A Kazerooni; Fernando J Martinez; Brian D Ross
Journal:  Nat Med       Date:  2012-10-07       Impact factor: 53.440

9.  Mortality and drug therapy in patients with chronic obstructive pulmonary disease: a network meta-analysis.

Authors:  David A Scott; Bethan Woods; Juliette C Thompson; James F Clark; Neil Hawkins; Mike Chambers; Bartolome R Celli; Peter Calverley
Journal:  BMC Pulm Med       Date:  2015-11-11       Impact factor: 3.317

10.  Health impact of E-cigarettes: a prospective 3.5-year study of regular daily users who have never smoked.

Authors:  Riccardo Polosa; Fabio Cibella; Pasquale Caponnetto; Marilena Maglia; Umberto Prosperini; Cristina Russo; Donald Tashkin
Journal:  Sci Rep       Date:  2017-11-17       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.